
1. Malar J. 2018 Nov 8;17(1):416. doi: 10.1186/s12936-018-2548-2.

Assessment of drug resistance associated genetic diversity in Mauritanian
isolates of Plasmodium vivax reveals limited polymorphism.

Mint Deida J(1)(2), Ould Khalef Y(3), Mint Semane E(4), Ould Ahmedou Salem MS(1),
Bogreau H(5)(6)(7), Basco L(6), Ould Mohamed Salem Boukhary A(8)(9), Tahar R(2).

Author information: 
(1)Unité de Recherche Génome et Milieux (JEAI), Faculté des Sciences et
Techniques, Université de Nouakchott Al-Aasriya, Nouveau campus universitaire, BP
5026, Nouakchott, Mauritania.
(2)Unité Mixte de Recherche 216 Mère et enfant face aux infections tropicales,
Institut de Recherche pour le Développement (IRD), Faculté de Pharmacie,
Université Paris Descartes, 4 avenue de l'Observatoire, 75270, Paris Cedex 06,
France.
(3)Service de Pédiatrie, Centre Hospitalier Mère et Enfant (CHME), Nouakchott,
Mauritania.
(4)Centre de santé de Teyarett, Nouakchott, Mauritania.
(5)Unité de Parasitologie et d'Entomologie, Institut de Recherche Biomédicale des
Armées, IHU-Méditerranée Infection, Marseille, France.
(6)Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée Infection,
Marseille, France.
(7)Centre National de Référence du Paludisme, Institut Hospitalo-Universitaire
(IHU) Méditerranée Infection, Marseille, France.
(8)Unité de Recherche Génome et Milieux (JEAI), Faculté des Sciences et
Techniques, Université de Nouakchott Al-Aasriya, Nouveau campus universitaire, BP
5026, Nouakchott, Mauritania. alimedsalem@gmail.com.
(9)Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée Infection,
Marseille, France. alimedsalem@gmail.com.

BACKGROUND: Plasmodium vivax is the predominant malaria species in northern
Mauritania. Molecular data on P. vivax isolates circulating in West Africa are
scarce. The present study analysed molecular markers associated with resistance
to antifolates (Pvdhfr and Pvdhps), chloroquine (Pvmdr1), and artemisinin (Pvk12)
in P. vivax isolates collected in two cities located in the Saharan zone of
Mauritania.
METHODS: Blood samples were obtained from P. vivax-infected patients recruited
for chloroquine therapeutic efficacy study in 2013 and febrile patients
spontaneously consulting health facilities in Nouakchott and Atar in 2015-2016.
Fragments of Pvdhfr (codons 13, 33, 57, 58, 61, 117, and 174), Pvdhps (codons
382, 383, 512, 553, and 585), Pvmdr1 (codons 976 and 1076) and Pvk12 (codon 552) 
genes were amplified by PCR and sequenced.
RESULTS: Most of the isolates in Nouakchott (126/154, 81.8%) and Atar (44/45,
97.8%) carried the wild-type Pvdhfr allelic variant (IPFSTSI). In Nouakchott, all
mutants (28/154; 18.2%) had double Pvdhfr mutations in positions 58 and 61
(allelic variant IPFRMSI), whereas in Atar only 1 isolate was mutant (S117N,
allelic variant IPFSTNI). The wild-type Pvdhps allelic variant (SAKAV) was found 
in all tested isolates (Nouakchott, n = 93; Atar, n = 37). Few isolates in
Nouakchott (5/115, 4.3%) and Atar (3/79, 3.8%) had the mutant Pvmdr1 allele 976F 
or 1076L, but not both, including in pre-treatment isolates obtained from
patients treated successfully with chloroquine. All isolates (59 in Nouakchott
and 48 in Atar) carried the wild-type V552 allele in Pvk12.
CONCLUSIONS: Polymorphisms in Pvdhfr, Pvdhps, Pvmdr1, and Pvk12 were limited in
P. vivax isolates collected recently in Nouakchott and Atar. Compared to the
isolates collected in Nouakchott in 2007-2009, there was no evidence for
selection of mutants. The presence of one, but not both, of the two potential
markers of chloroquine resistance in Pvmdr1 in pre-treatment isolates did not
influence the clinical outcome, putting into question the role of Pvmdr1 mutant
alleles 976F and 1076L in treatment failure. Molecular surveillance is an
important component of P. vivax malaria control programme in the Saharan zone of 
Mauritania to predict possible emergence of drug-resistant parasites.

DOI: 10.1186/s12936-018-2548-2 
PMCID: PMC6225721
PMID: 30409138  [Indexed for MEDLINE]

